The Emerging Innovations in Psychedelic Healthcare conference, held by the team behind PSYCH Symposium, is bringing together a wealth of experts to evaluate and accelerate the industry.
The psychedelic healthcare market is currently projected to reach a value of US£5 billion by 2028, however, hurdles such as the regulation of psychedelic substances still pose a challenge to the industry.
The event, which coincides with the release of The Psychedelics as Medicine Report: Fourth Edition and Jefferies 2022 London Healthcare Conference, will be exploring the commercialisation of psychedelic medicine.
Contributors to The Psychedelics as Medicine Report: Fourth Edition will be discussing the market’s potential.
Experts will also explore milestones in the adoption of psychedelic care through open panel discussions, fireside interviews and facilitated networking.
The programme includes:
- A fireside interview with Cybin CEO, Doug Drysdale, on the future of psychedelic healthcare and investment.
- A panel discussion on ketamine, MDMA and psilocybin-assisted therapy market sizing.
- A fireside interview with Vadim Uzberg, Partner at Negev Capital.
Awakn Life Sciences will also be presenting at the event.
Grace Cook, Commercial Director at PSYCH Global, commented: “2022 has seen some considerable hurdles for the psychedelic healthcare industry.
“At this important event, we will be discussing the commercialisation of psychedelics as we head into the next five years.
“We’re excited to bring key figures together in London for an afternoon of information sharing and networking.”
Attendees will have the opportunity to network with industry leaders in an intimate setting of an estimated 50 people.
PSYCH Global will be holding Emerging Innovations in Psychedelic Healthcare on 17 November from 4.00 pm to 7.30 pm at the Sea Containers, London.
The event is by invitation only, so please register if interested in attending at: https://psych.global/innovations-in-psychedelic-healthcare/
